Siemens Healthineers debuted the FlexForce Coach performance consulting and FlexForce Tech staffing solutions, which are ...

Fujifilm Medical Systems U.S.A. Inc. announced that it will offer educational opportunities and exhibit its latest innovations in digital radiography (DR), women’s health and pediatric imaging portfolio at the Association for Medical Imaging Management (AHRA) 2018 Annual Meeting and Exposition, July 22-25 in Orlando, Fla.

A novel new study provides compelling evidence that the design, development and implementation of electronic health records (EHRs) need to be improved to make them easier to use by clinicians and, ultimately, safer for patients.

A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization.

A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history. The blood test captures risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology.

iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular imaging analysis platform in Australia and New Zealand. Hospitals and clinics that treat ischemic stroke in these countries will now have access to RAPID’s automated computed tomography perfusion (CTP), magnetic resonance (MR), CT angiography (CTA) and ASPECTS solutions, with support from DIA’s customer service specialists in the region.

Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new therapies with great potential actually have clear benefits over usual care for patients. However, the seven randomized trials funded by the National Cancer Institute (NCI) and the Patient Centered Outcomes Research Institute (PCORI) to test proton therapy are enrolling more slowly than expected. Commercial insurance medical policies that do not cover treatment with proton therapy can make it difficult for patients to participate in randomized clinical trials funded by the NCI, part of the National Institutes of Health, that are evaluating the therapy. That’s the message from an expert at the Perelman School of Medicine at the University of Pennsylvania and colleagues at the NCI who are calling attention to what the authors say is a major barrier these trials face. The authors publish their commentary, and proposed solutions, this week in the Journal of Clinical Oncology.